Elanco Animal Health Acquires Boehringer Ingelheim Vetmedica’s U.S. Feline, Canine and Rabies Vaccines Portfolio
January 03, 2017
NEW YORK – Paul Hastings LLP, a leading global law firm, announced today that the firm represented Elanco US Inc., a division of Eli Lilly and Company, in the completion of its approximately $885 million acquisition of Boehringer Ingelheim Vetmedica’s U.S. feline, canine and rabies vaccines portfolio, along with a fully integrated manufacturing and R&D site and several pipeline assets.
The acquisition diversifies Elanco’s U.S. companion animal portfolio by adding vaccines for a range of common concerns, including bordetella, Lyme disease, feline leukemia, rabies, and parvovirus.
The Paul Hastings team was led by Mergers and Acquisitions partner David Shine, and included associates Leslie Kersey, Rachel Harrison, Jennifer Tytel, Jordan Goldman, Sean Murphy, Dee Kuchukulla, Michael DiRaimo and Annie Wang from the Mergers and Acquisitions practice. The Paul Hastings team also included partners Sam Waxman and Jane Song and associates Todd Schneider and Michael Vargas, who advised on Intellectual Property matters; partner, Lisa Rushton, who advised on Environmental matters; partner Bruce DePaola and associate Alyssa Lust, who advised on Real Estate matters; partner Joe Opich and associate Eileen Kuo, who advised on Tax matters; and partner Eric Keller, who advised on Employment and Benefits matters. Partner Charles Patrizia also advised on the transaction.
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.